Basilea Pharmaceutica

Clinical trials sponsored by Basilea Pharmaceutica, explained in plain language.

Basilea Pharmaceutica BSLN SIX SWISS

A pharmaceutical company developing treatments for infectious diseases and cancer.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

New antibiotic combo tested in healthy volunteers – no cure yet Results expected Dec 2026 (estimated)
New antibiotic candidate enters first human safety trial Results expected Jun 2027 (estimated)

Browse trials soon ready across all sponsors →

Trials to join now! 4 Completed 14 Terminated 1

New hope against deadly molds? early trial cut short

Disease control Stopped early

This study tested a drug called fosmanogepix in 21 adults with invasive mold infections (like Aspergillus or rare molds) who had few other options. The trial was stopped early, so we have limited data on how well it works or its safety.

Phase 2 • Sponsor: Basilea Pharmaceutica • Aim: Disease control

Last updated Jun 26, 2026 17:54 UTC

Basilea Pharmaceutica

Upcoming readouts

New hope against deadly molds? early trial cut short